Prospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Nov 14, 2024; 30(42): 4532-4543
Published online Nov 14, 2024. doi: 10.3748/wjg.v30.i42.4532
Figure 4
Figure 4 Drug sensitivity analysis and clinical relevance of organoids. A: Curve drug sensitivity curves of patients No. 1; B: Curve drug sensitivity curves of patients No. 2; C: Curve drug sensitivity curves of patients No. 14; D: Listed the sensitive drugs and clinical protocols for No. 9 patients. Assessment of resectable patients according to National Comprehensive Cancer Network guidelines: Unresectable, local progression, borderline resectable. Patient tumor response was measured using RESIST 1.1 criteria and categorized as partial response, stable disease, and progressive disease. AG: Gemcitabine combined with albumin-paclitaxel; mFFX: Modified FOLFIRINOX, oxaliplatin, irinotecan, fluorouracil and calcium leucovorin; UR: Unresectable; LP: Local progression; BR: Borderline resectable; 5-Fu: Fluorouracil; PD: Progressive disease; SD: Stable disease; PR: Partial response; OS: Overall survival; PFS: Progression-free survival.